跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
MINT-ATORVASTATIN - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
MINT-ATORVASTATIN
Authorized
STANDARD
MINT-ATORVASTATIN
mint pharmaceuticals inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
a2adeb180ef15d01
Company
mint pharmaceuticals inc
Type
Standard
Approval Details
Approval Id
a2adeb180ef15d01
Drug Approval Canada Name
MINT-ATORVASTATIN
Product Name
MINT-ATORVASTATIN
Status
Marketed
Status Date
2023-12-28
Original Market Date
2023-12-28
Din
02479532
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
Prescription
Ahfs
24:06.08
Atc Original
C10AA05 ATORVASTATIN
Atc Name
c 10 aa 05
Aig Number
0133055004
Company Name
mint pharmaceuticals inc
Company Address
6575 Davand Drive, Mississauga, Ontario, Canada, L5T 2M3
Active Ingredients
ATORVASTATIN (ATORVASTATIN CALCIUM)
80 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
a2adeb180ef15d01
Type
Standard
Back to Health Canada Approvals